These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 18533605)
21. Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome. Derosa G; Maffioli P N Engl J Med; 2016 Mar; 374(11):1095. PubMed ID: 26981947 [No Abstract] [Full Text] [Related]
22. Dipeptidyl peptidase-iV inhibitors: fixing type 2 diabetes? McIntyre HF; Grant P Br J Hosp Med (Lond); 2007 Nov; 68(11):599-602. PubMed ID: 18087847 [TBL] [Abstract][Full Text] [Related]
23. Choosing among the incretin agents and why it matters. Unger J J Fam Pract; 2010 May; 59(5 Suppl):S30-5. PubMed ID: 20544056 [No Abstract] [Full Text] [Related]
24. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Drucker DJ; Nauck MA Lancet; 2006 Nov; 368(9548):1696-705. PubMed ID: 17098089 [TBL] [Abstract][Full Text] [Related]
25. Hypoglycemics for the treatment of type 2 diabetes in patients with chronic kidney disease: a focus on new agents. Fang V; Wazny LD; Raymond CB CANNT J; 2012; 22(1):30-6; quiz 37-8. PubMed ID: 22558681 [No Abstract] [Full Text] [Related]
27. Exenatide in combination therapy: small study, big market, and many unanswered questions. Malozowski S Ann Intern Med; 2007 Apr; 146(7):527-8. PubMed ID: 17404355 [No Abstract] [Full Text] [Related]
29. [Reply on new drugs against type 2 diabetes: important to gain experience and knowledge]. Sjöholm A; Agardh CD; Brismar K; Efendic S; Eliasson B; Eriksson JW; Frid A; Groop L; Holmgren J; Ridderstråle M; Smith U Lakartidningen; 2008 Apr 23-May 6; 105(17-18):1310, 1312. PubMed ID: 18561535 [No Abstract] [Full Text] [Related]
30. Application of incretin mimetics and dipeptidyl peptidase IV inhibitors in managing type 2 diabetes mellitus. Boyle PJ; Freeman JS J Am Osteopath Assoc; 2007 May; 107 Suppl():S10-6. PubMed ID: 17724013 [TBL] [Abstract][Full Text] [Related]
31. [New medications for patients with type 2 diabetes]. Meillet L Soins; 2014 Oct; (789):15-8. PubMed ID: 25518129 [TBL] [Abstract][Full Text] [Related]
32. Options for combination therapy in type 2 diabetes: comparison of the ADA/EASD position statement and AACE/ACE algorithm. Bailey T Am J Med; 2013 Sep; 126(9 Suppl 1):S10-20. PubMed ID: 23953074 [TBL] [Abstract][Full Text] [Related]
34. Incretin therapies in the management of elderly patients with type 2 diabetes mellitus. Bourdel-Marchasson I; Schweizer A; Dejager S Hosp Pract (1995); 2011 Feb; 39(1):7-21. PubMed ID: 21441754 [TBL] [Abstract][Full Text] [Related]
35. [Treatment with new preparations against type 2 diabetes not sufficiently documented]. Karlsson EA; Palmér M; Malmström R Lakartidningen; 2008 Feb 27-Mar 4; 105(9):647-8; author reply 648-9. PubMed ID: 18376713 [No Abstract] [Full Text] [Related]
36. Pharmacotherapy: Cardiovascular safety of antihyperglycaemic drugs in patients with type 2 diabetes mellitus. Greenhill C Nat Rev Endocrinol; 2013 Nov; 9(11):625. PubMed ID: 24061081 [No Abstract] [Full Text] [Related]
37. Missing the point: substituting exenatide for nonoptimized insulin: going from bad to worse! Rosenstock J; Fonseca V Diabetes Care; 2007 Nov; 30(11):2972-3. PubMed ID: 17965313 [No Abstract] [Full Text] [Related]
38. Exenatide and rare adverse events. Ahmad SR; Swann J N Engl J Med; 2008 May; 358(18):1970-1; discussion 1971-2. PubMed ID: 18456920 [No Abstract] [Full Text] [Related]
39. [The value of incretin based therapies]. Gallwitz B Dtsch Med Wochenschr; 2009 May; 134(20):1062-6. PubMed ID: 19421931 [No Abstract] [Full Text] [Related]
40. An analysis of characteristics of subjects examined for incretin effects on pancreatic pathology. Harja E; Lord J; Skyler JS Diabetes Technol Ther; 2013 Aug; 15(8):609-18. PubMed ID: 23927624 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]